Annals of Nuclear Medicine最新文献

{"title":"Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review","authors":"Priscilla Guglielmo,&nbsp;Nicolò Buffi,&nbsp;Angelo Porreca,&nbsp;Lucia Setti,&nbsp;Demetrio Aricò,&nbsp;Lorenzo Muraglia,&nbsp;Laura Evangelista","doi":"10.1007/s12149-025-02015-w","DOIUrl":"10.1007/s12149-025-02015-w","url":null,"abstract":"<div><p>The purpose of this systematic review was to evaluate the role of PSMA PET/CT in intermediate-risk prostate cancer (PCa) patients, to determine whether it could help improve treatment strategy and prognostic stratification. A systematic literature search up to May 2024 was conducted in the PubMed, Embase and Scopus databases. Articles with mixed risk patient populations, review articles, editorials, letters, comments, or case reports were excluded. The quality of the papers was assessed by using the CASP criteria. The literature search returned 1111 studies; however, 1105 articles were excluded, and therefore 6 full-text papers were retrieved for the final analysis. Three out of six papers focused on the utility of SUVmax in identifying high ISUP grade in patients with intermediate-risk PCa. The latest three papers discussed the controversial role of PSMA PET/CT in predicting the lymph node involvement, mainly in the case of favorable subset. PSMA PET has completely changed the management of patients with PCa; indeed its role is still undefined in patients with intermediate-risk disease. Future perspective is to investigate larger cohorts of intermediate-risk PCa patients, to fully recognize the added value offered by PSMA PET in this category of subjects.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 3","pages":"247 - 254"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First study on the efficiency of 99mTc-rituximab for sentinel lymph node mapping and biopsy in oral squamous cell carcinoma","authors":"Yang Liu,&nbsp;Fei Wang,&nbsp;Yufei Song,&nbsp;Xiaochuan Zhou,&nbsp;Xin Zhou,&nbsp;Changzhi Du,&nbsp;Yan Cui,&nbsp;Yitong Liu,&nbsp;Nan Li","doi":"10.1007/s12149-024-02012-5","DOIUrl":"10.1007/s12149-024-02012-5","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the clinical efficiency of using the sentinel lymph node (SLN) imaging agent ^99mTc-rituximab for lymphoscintigraphy and SLN biopsy (SLNB) in oral squamous cell carcinoma (OSCC) patients.</p><h3>Methods</h3><p>A retrospective study was conducted on 23 patients with OSCC who underwent ^99mTc-rituximab lymphoscintigraphy and SLNB. The cohort comprised 16 men (69.6%) and 7 women (30.4%) with a median age of 64.0 years (range: 33–90 years). All patients received a preoperative peritumoral injection of ^99mTc-rituximab. The SLN detection rates (SDRs) of SLN imaging and SLNB were analyzed. The localizations of SLNs were counted. Patients were followed up after surgery. Differences were considered significant for a <i>p</i>-value of less than 0.05.</p><h3>Results</h3><p>The SDRs of lymphoscintigraphy and SLNB were 91.3% (21/23) and 100.0% (23/23), respectively. The SDRs of lymphoscintigraphy for patients in pathological stages I/II and III/IVa were 100.0% (15/15) and 75.0% (6/8), respectively. Among the 2 patients with negative imaging results, both were stage IVa and both had SLN metastasis. The SLNs were located in levels Ib, IIa, IIb, III, and IV, accounting for 45.0% (18/40), 40.0% (16/40), 10.0% (4/40), 2.5% (1/40), and 2.5% (1/40), respectively. The median follow-up duration was 32.0 months (range: 13.0–68.0 months). During follow-up, none of the 23 patients (100.0%) showed lymph node (LN) metastasis. As a result, the sensitivity, negative predictive value (NPV), and accuracy were all 100.0%.</p><h3>Conclusions</h3><p>The application of ^99mTc-rituximab for SLN imaging and SLNB in OSCC patients demonstrated high detection rates and accuracy, holding significant clinical value.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 4","pages":"380 - 387"},"PeriodicalIF":2.5,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of quantitative [18F]NaF PET uptake parameters in bone diseases: a systematic review","authors":"Ruben D. de Ruiter,&nbsp;Jolien Zwama,&nbsp;Pieter G. H. M. Raijmakers,&nbsp;Maqsood Yaqub,&nbsp;George L. Burchell,&nbsp;Ronald Boellaard,&nbsp;Adriaan A. Lammertsma,&nbsp;Elisabeth M. W. Eekhoff","doi":"10.1007/s12149-024-01991-9","DOIUrl":"10.1007/s12149-024-01991-9","url":null,"abstract":"<div><h3>Purpose</h3><p>[¹⁸F]NaF PET has become an increasingly important tool in clinical practice toward understanding and evaluating diseases and conditions in which bone metabolism is disrupted. Full kinetic analysis using nonlinear regression (NLR) with a two-tissue compartment model to determine the net rate of influx (<i>K</i>_<i>i</i>) of [¹⁸F]NaF is considered the gold standard for quantification of [¹⁸F]NaF uptake. However, dynamic scanning often is impractical in a clinical setting, leading to the development of simplified semi-quantitative parameters. This systematic review investigated which uptake parameters have been used to evaluate bone disorders and how they have been validated to measure disease activity.</p><h3>Methods</h3><p>A literature search (in PubMed, Embase.com, and Clarivate Analytics/Web of Science Core Collection) was performed up to 28th November 2023, in collaboration with an information specialist. Each database was searched for relevant literature regarding the use of [¹⁸F]NAF PET/CT to measure disease activity in bone-related disorders. The main aim was to explore whether the reported semi-quantitative uptake values were validated against full kinetic analysis. A second aim was to investigate whether the chosen uptake parameter correlated with a disease-specific outcome or marker, validating its use as a clinical outcome or disease marker.</p><h3>Results</h3><p>The initial search included 1636 articles leading to 92 studies spanning 29 different bone-related conditions in which [¹⁸F]NaF PET was used to quantify [¹⁸F]NaF uptake. In 12 bone-related disorders, kinetic analysis was performed and compared with simplified uptake parameters. SUV_mean (standardized uptake value) and SUV_max were used most frequently, though normalization of these values varied greatly between studies. In some disorders, various studies were performed evaluating [¹⁸F]NaF uptake as a marker of bone metabolism, but unfortunately, not all studies used this same approach, making it difficult to compare results between those studies.</p><h3>Conclusion</h3><p>When using [¹⁸F]NaF PET to evaluate disease activity or treatment response in various bone-related disorders, it is essential to detail scanning protocols and analytical procedures. The most accurate outcome parameter can only be obtained through kinetic analysis and is better suited for research. Simplified uptake parameters are better suited for routine clinical practice and repeated measurements.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 2","pages":"98 - 149"},"PeriodicalIF":2.5,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-024-01991-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging of cardiac amyloidosis using dynamic 18F-FPYBF-2 positron emission tomography","authors":"Chio Okuyama,&nbsp;Yasutaka Inuzuka,&nbsp;Yuzo Takeuchi,&nbsp;Kohsuke Asagoe,&nbsp;Shinya Kagawa,&nbsp;Miki Ito,&nbsp;Kuninori Kusano,&nbsp;Yoshiharu Fujita,&nbsp;Hiroyuki Watanabe,&nbsp;Masahiro Ono,&nbsp;Tatsuya Higashi","doi":"10.1007/s12149-024-02010-7","DOIUrl":"10.1007/s12149-024-02010-7","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to evaluate the diagnostic ability of 5-(5-(2-(2-(2-¹⁸F-fluoroethoxy) ethoxy) ethoxy) benzofuran-2-yl)-N-methylpyridin-2-amine (¹⁸F-FPYBF-2) dynamic PET for patients with cardiac amyloidosis (CA).</p><h3>Methods</h3><p>The subjects were patients diagnosed with proven amyloidosis (<i>n</i> = 16) including transthyretin cardiac amyloidosis (ATTR-CA) (<i>n</i> = 7) and light chain amyloidosis (AL amyloidosis) (<i>n</i> = 9), of which 4 and 5 with (AL-CA) and without (AL-nCA) cardiac involvement, and 4 control subjects suffering from some symptoms of cardiac failure without amyloidosis (CTL). Thirty minutes dynamic ¹⁸F-FPYBF-2 PET/CT was performed to evaluate the time activity curve and the retention index (mRI) as the ratio of the myocardial SUV at 15 to 5 min. The results of bone scan were also evaluated except for 2 AL-nCA cases.</p><h3>Results</h3><p>Diffuse ¹⁸F-FPYBF-2 distribution in the myocardium was observed within a few minutes in all cases. The accumulation was still seen at 30 min after injection in all the CA cases, while it showed rapid clearance in CTL and AL-nCA cases. The values mRI of the ATTR-CA and AL-CA were significantly higher than CTL and AL-nCA cases, and AL-CA showed higher value than ATTR-CA (p &lt; 0.05), while the positive results of bone scan were observed in all ATTR-CA cases, and in one case of AL-CA.</p><h3>Conclusions</h3><p>¹⁸F-FPYBF-2 PET could be a useful tool to evaluate cardiac involvement of amyloidosis and can visualize AL-CA regardless of the results of bone scan.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 4","pages":"398 - 403"},"PeriodicalIF":2.5,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of modified Curie and SIOPEN skeleton scoring systems in 18F-AlF-NOTA-octreotide PET/CT for neuroblastoma","authors":"Siqi Li,&nbsp;Baojun Sang,&nbsp;Jun Liu,&nbsp;Yuxuan Liu,&nbsp;Yanfeng Xu,&nbsp;Xiaorong Sun,&nbsp;Jigang Yang","doi":"10.1007/s12149-024-02006-3","DOIUrl":"10.1007/s12149-024-02006-3","url":null,"abstract":"<div><h3>Objective</h3><p>The study aimed to explore the role of fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide (¹⁸F-OC) positron emission tomography/computed tomography (PET/CT) in neuroblastoma (NB) and compared it with Iodine-123 labeled metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy with single photon emission computed tomography/computed tomography (SPECT/CT), as well as to investigate the feasibility of the modified Curie scoring system and International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) skeleton scoring system applied in ¹⁸F-OC PET/CT.</p><h3>Methods</h3><p>Patients with pathologically confirmed NB underwent ¹²³I-MIBG scintigraphy with SPECT/CT and ¹⁸F-OC PET/CT according the standard imaging protocols. The interval between the two imaging techniques ranged from 0 to 22 days (median interval: 9 days). The number of lesions in modified Curie scoring system and SIOPEN skeleton scoring system applied on ¹²³I-MIBG SPECT/CT and ¹⁸F-OC PET/CT was compared.</p><h3>Results</h3><p>A total of 50 NB patients (male: female = 25:25) with a median age of 62-month-old were enrolled. ¹²³I-MIBG and ¹⁸F-OC imaging were positive in 22 patients and negative in 27 patients. 1 patient had positive ¹⁸F-OC but negative ¹²³I-MIBG results (<i>p</i> = 1.000). In lesion-based analysis, ¹⁸F-OC PET/CT revealed more positive lesions than ¹²³I-MIBG scintigraphy with SPECT/CT (57 vs. 44, <i>p</i> &lt; 0.001), regardless of bone/bone marrow lesions (43 vs. 37, <i>p</i> = 0.031) or soft tissue lesions (14 vs. 7, <i>p</i> = 0.016). The Curie scores of the two imaging techniques showed a significant difference (<i>p</i> = 0.047), whereas no statistic difference for SIOPEN scores (<i>p</i> = 0.688). The Curie and SIOPEN scores were significantly higher in patients with the presence of MYCN amplification or positive bone marrow puncture result (<i>p</i> &lt; 0.05).</p><h3>Conclusion</h3><p>¹⁸F-OC could be used in the evaluation of NB, and the modified Curie scoring system could be used to semi-quantify the disease extent of NB in ¹⁸F-OC PET/CT.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 4","pages":"353 - 363"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiolabelled anti-PD-L1 peptide PET/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer","authors":"Xin Zhou,&nbsp;Shi Yan,&nbsp;Dan Li,&nbsp;Hua Zhu,&nbsp;Bing Liu,&nbsp;Shiwei Liu,&nbsp;Wei Zhao,&nbsp;Zhi Yang,&nbsp;Nan Wu,&nbsp;Nan Li","doi":"10.1007/s12149-024-02009-0","DOIUrl":"10.1007/s12149-024-02009-0","url":null,"abstract":"<div><h3>Background</h3><p>This study aimed to evaluate the predictive value of baseline PD-L1 targeted peptide ⁶⁸Ga-NOTA-WL12 PET/CT in neoadjuvant immunotherapy combined with chemotherapy of resectable NSCLC.</p><h3>Methods</h3><p>Patients with resectable NSCLC (<i>n</i> = 20) enrolled in this prospective study received baseline paired ⁶⁸Ga-NOTA-WL12 PET/CT and ¹⁸F-FDG PET/CT. After 2–4 cycles of toripalimab plus nab-paclitaxel and cisplatin, surgery was performed if R0 resection was available. The major pathologic response (MPR) state of the post-operative specimen was recorded. The imaging parameters of the ⁶⁸Ga-NOTA-WL12 PET/CT, ¹⁸F-FDG PET/CT and CT between the MPR and non-MPR groups and their predictive efficacy of MPR were compared.</p><h3>Results</h3><p>Among 20 patients, 17 patients underwent surgery, 10 achieved an MPR and 7 did not. The SUV_max and tumour-to-blood pool (TBR) of baseline ⁶⁸Ga-NOTA-WL12 in the MPR group were higher than those in the non-MPR group, and the difference in TBR was statistically significant. The ΔSUL_peak% of ¹⁸F-FDG exhibited differences between the MPR and non-MPR groups with no significance. Baseline ¹⁸F-FDG PET/CT parameters and Δ<i>D</i>% failed to differentiate the two groups. The areas under the ROC curves of SUV_max, TBR in ⁶⁸Ga-NOTA-WL12 PET/CT, Δ<i>D</i>% and ΔSUL_peak% in ¹⁸F-FDG PET/CT were 0.76, 0.79, 0.71 and 0.80, respectively, in predicting MPR.</p><h3>Conclusion</h3><p>Baseline ⁶⁸Ga-NOTA-WL12 PET/CT has a potential to predict the pathological response of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable NSCLC, whose efficacy is comparable to that of therapy evaluations employing baseline and follow-up CT and ¹⁸F-FDG PET/CT examinations.</p><p><i>Trial registration</i>: NCT04304066, registered 13 November 2020, https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AEI9&amp;selectaction=Edit&amp;uid=U000503E&amp;ts=2&amp;cx=-awajet.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 4","pages":"364 - 372"},"PeriodicalIF":2.5,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of a new anthropomorphic phantom simulating the chest and abdomen regions in PET tests","authors":"Hiroaki Sagara,&nbsp;Kazumasa Inoue,&nbsp;Chikara Mano,&nbsp;Hironori Kajiwara,&nbsp;Yuichi Nagai,&nbsp;Hirofumi Fujii,&nbsp;Anri Inaki","doi":"10.1007/s12149-024-02007-2","DOIUrl":"10.1007/s12149-024-02007-2","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the clinical utility of a new anthropomorphic phantom that reproduces the chest and abdomen better than the conventional National Electrical Manufacturers Association (NEMA) body phantom, count rates and image quality of PET images obtained from patients were evaluated.</p><h3>Methods</h3><p>Anthropomorphic phantoms were used to include radioactivity in the lung, liver, kidney, and background regions. Two NEMA body phantoms were used for chest and abdominal assessments. The cross calibration factor (CCF) cylinder phantom was also used to reproduce the distribution of radioactivity outside the field of view, simulating the patient brain. Four types of phantoms were used in the PET imaging experiment, and for each phantom, the prompt coincidence count rates, random coincidence count rates, true + scatter coincidence count rates, and single photon count rates were measured. Then, these count rates were compared with count rates from actual clinical data. PET image quality assessment was done using the parameters, noise equivalent count patient (NEC_patient), noise equivalent count density (NEC_density), and liver signal-to-noise ratio (SNR).</p><h3>Results</h3><p>Random coincidence count rates showed that the data obtained from each phantom were in good agreement with the clinical data. True + scatter coincidence count rates had better agreement with clinical data when measured for anthropomorphic phantoms than for the NEMA body phantoms. Furthermore, when the CCF Cylinder phantom simulating the brain was placed outside the imaging field of view, the results were closer to the clinical data. PET image quality was 1.4% higher for NEC_patient obtained from anthropomorphic phantoms compared to the mean obtained from clinical data. NEC_density was 15.0% lower than the mean value obtained from clinical data. Liver SNR was 14.8% higher in PET images reconstructed using the 3D-ordered subsets expectation maximization (OSEM) method. It was 10.0% lower in PET images reconstructed with the image reconstruction method Q.Clear (GE Healthcare) using the Bayesian penalized likelihood (BPL) method.</p><h3>Conclusion</h3><p>The new anthropomorphic phantom was more consistent with the count rates obtained from clinical data than the conventional NEMA body phantoms were and it was able to better simulate the distribution of radioactivity concentrations in the patients by reproducing the distribution of radioactivity concentrations outside the field of view.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 3","pages":"303 - 312"},"PeriodicalIF":2.5,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-024-02007-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of 18F-fluorodeoxyglucose uptake for axillary lymph node metastasis in operable breast cancer: impact of molecular subtypes","authors":"Chae Hong Lim,&nbsp;Jun-Hee Lee,&nbsp;Jihyoun Lee,&nbsp;Soo Bin Park","doi":"10.1007/s12149-024-02002-7","DOIUrl":"10.1007/s12149-024-02002-7","url":null,"abstract":"<div><h3>Objectives</h3><p>To evaluate the predictive value of standardized uptake value (SUV) in both primary tumors and axillary lymph nodes (ALNs) using FDG PET/CT for lymph node metastasis in breast cancer patients, and to assess the influence of molecular subtypes on this predictive performance.</p><h3>Methods</h3><p>This retrospective study included 287 patients with invasive ductal carcinoma (IDC) who underwent FDG PET/CT prior to surgery between September 2016 and December 2019. The maximum standardized uptake value (SUV_max) of primary tumors (SUV-B) and ALNs (SUV-LN) were analyzed. Molecular subtypes were classified as hormone receptor-positive, HER2-positive, and triple-negative breast cancer (TNBC). Receiver operating characteristic (ROC) curve analysis was performed to assess and compare the diagnostic performance of SUV-B and SUV-LN for predicting ALN metastasis.</p><h3>Results</h3><p>Among the 287 patients, 62 (21.6%) had confirmed ALN metastasis. The median SUV-LN was significantly higher in patients with metastasis compared to those without metastasis (1.5 vs. 0.9; <i>P</i> &lt; 0.001). SUV-LN demonstrated good discriminative performance for ALN metastasis (AUC: 0.796), whereas SUV-B did not show significant predictive value (AUC: 0.536). The SUV_LN demonstrated significantly lower predictive performance for ALN metastasis in the hormone-positive group (AUC: 0.796) compared to the excellent discriminative performance in the HER2-positive (AUC: 0.923, <i>P</i> = 0.018) and TNBC (AUC: 0.940, <i>P</i> = 0.004) groups. Hormone receptor-positive tumors also exhibited lower FDG uptake in metastatic lymph nodes compared to HER2-positive and TNBC subtypes (<i>P</i> = 0.031).</p><h3>Conclusion</h3><p>FDG PET/CT SUV-LN effectively predicts ALN metastasis in HER2-positive and TNBC subtypes. Hormone receptor-positive breast cancers show lower FDG uptake in metastatic ALNs, reducing diagnostic accuracy. This finding may aid in selecting the most appropriate diagnostic modality based on tumor characteristics in the era of personalized medicine.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 4","pages":"315 - 322"},"PeriodicalIF":2.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of position emission tomography derived endocardial wall strain: direct comparison with magnetic resonance using hybrid 13N ammonia PETMR system","authors":"Masataka Katahira,&nbsp;Kenji Fukushima,&nbsp;Keiichiro Endo,&nbsp;Masateru Kawakubo,&nbsp;Naoyuki Ukon,&nbsp;Ryo Yamakuni,&nbsp;Takatoyo Kiko,&nbsp;Takeshi Shimizu,&nbsp;Shiro Ishii,&nbsp;Takayoshi Yamaki,&nbsp;Michinobu Nagao,&nbsp;Hiroshi Ito,&nbsp;Yasuchika Takeishi","doi":"10.1007/s12149-024-01997-3","DOIUrl":"10.1007/s12149-024-01997-3","url":null,"abstract":"<div><h3>Purpose</h3><p>We aimed to evaluate the feasibility of positron emission tomography feature tracking (PETFT) for assessing endocardial wall strain by comparing it with cardiac magnetic resonance (CMR)-derived feature tracking (CMRFT).</p><h3>Methods</h3><p>We enrolled 83 consecutive patients with coronary artery disease who underwent rest-pharmacologic stress ¹³N-ammonia PETMR (67 males, mean age 66 years). PETFT and CMRFT were obtained through simultaneous acquisition with electrocardiography-gated PET and cine-CMR. Global longitudinal and circumferential strain (GLS and GCS) were calculated. Correlations and Bland–Altman plots were employed to evaluate associations, bias, and 95% limit of agreement (LOA) between PETFT and CMRFT.</p><h3>Results</h3><p>PETFT and CMRFT showed significant correlations (<i>R</i> = 0.57 [95% CI 0.41–0.70], <i>R</i> = 0.71 [95% CI 0.58–0.80], <i>R</i> = 0.59 [95% CI 0.43–0.71], and <i>R</i> = 0.69 [95% CI 0.56–0.79] for rest GLS, rest GCS, stress GLS, and stress GCS, respectively; <i>p</i> &lt; 0.001 for all). Bland–Altman plot showed good agreements, while a systematic error was observed (LOA -10.2–8.8, -8.7–10.7, -10.5–8.5, and -9.4–12.0; bias -0.7, 1.0, -1.0, and 1.3; for rest GLS, rest GCS, stress GLS, and stress GCS; respectively).</p><h3>Conclusion</h3><p>PETFT has been identified as a feasible technique compared to CMRFT, highlighting its potential as a novel tool for assessing wall strain in routine clinical settings.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 3","pages":"285 - 294"},"PeriodicalIF":2.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 13th World Federation of Nuclear Medicine and Biology congress (WFNMB 2022): summarize the past half century and discuss the next half century of WFNMB-","authors":"Hirofumi Fujii,&nbsp;Hiroshi Toyama,&nbsp;Daiki Kayano,&nbsp;Kazunari Ishii,&nbsp;Seigo Kinuya","doi":"10.1007/s12149-024-01999-1","DOIUrl":"10.1007/s12149-024-01999-1","url":null,"abstract":"<div><p>The 13th World Federation of Nuclear Medicine and Biology congress (WFNMB 2022) was held in Kyoto and Kanazawa, Japan in September 2022, approximately half a century after the first World Congress of Nuclear Medicine held in Tokyo and Kyoto, Japan. In this paper, we describe the road to hosting another WFNMB congress in Japan, including the historic election for WFNMB 2022, the state of WFNMB 2022 in Kyoto, and the post-congress symposium in Kanazawa. This congress, themed “Summarize the past half century and discuss the next half century of WFNMB,” was successful and strongly encouraged doctors and researchers to develop future research and clinical practice in nuclear medicine.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 2","pages":"87 - 97"},"PeriodicalIF":2.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}